Spots Global Cancer Trial Database for EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
Official Title: A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection With Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients
Study ID: NCT03266653
Interventions
Study Description
Brief Summary: Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Detailed Description:
Keywords
Eligibility
Minimum Age: 1 Month
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Children's Hosptial Los Angeles, Los Angeles, California, United States
University of California San Francisco, San Francisco, California, United States
Johns Hopkins, Baltimore, Maryland, United States
Washington University, Saint Louis, Missouri, United States
New York Medical College, Valhalla, New York, United States
Nationwide Children's Hosptial, Columbus, Ohio, United States
Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania, United States
Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Contact Details
Name: Mitchell Cairo, MD
Affiliation: New York Medical College
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
